


ABSTRACT

A prostaglandin derivative represented by the formula:



- wherein X is a halogen atom in the α - or β -position, Y is
- 5 an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formula: $O(CH_2)_n$, $S(O)_p(CH_2)_n$, $O(CH_2)_qO(CH_2)_r$, $O(CH_2)_qS(O)_p(CH_2)_r$,
- 10 $S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or $S(O)_p(CH_2)_qO(CH_2)_r$ (wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1), R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl- C_{3-10}
- 15 cycloalkyl group, a C_{3-10} cycloalkyl- C_{1-4} alkyl group, a C_{5-10} alkyl group, a C_{5-10} alkenyl group, a C_{5-10} alkynyl group or a bridged cyclic hydrocarbon group, R^2 is a hydrogen atom, a C_{1-10} alkyl group or a C_{3-10} cycloalkyl group, and
- 20 m is 0, 1 or 2], a pharmaceutically acceptable salt thereof or a hydrate thereof.

The present invention is to provide novel PG

derivatives having an excellent PGD₂-like agonistic activity and a sleep-inducing action.